HX531

HX531 is a potent and selective small molecule antagonist of the Retinoid X Receptors (RXRs), including the alpha (RXRα), beta (RXRβ), and gamma (RXRγ) isoforms. Originally developed to investigate the physiological roles of RXRs, HX531 has become a standard research tool for studying lipid metabolism, glucose homeostasis, and inflammatory responses. In the context of metabolic diseases, HX531 has demonstrated the ability to suppress diet-induced obesity and improve insulin sensitivity in animal models. More recently, research presented at ECCO 2024 highlighted its potential in treating Crohn's disease-like gut inflammation by blocking RXRα-mediated transcription of pro-inflammatory chemokines like CXCL1 in Paneth cells. While primarily utilized as a laboratory reagent, its efficacy in preclinical models of inflammatory bowel disease (IBD) suggests its potential as a lead compound for future therapeutic development.

Other names

4-(2-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl]-1,3-dithiolan-2-yl)benzoic acid